Description:
Formoterol and Glycopyrrolate Inhaler is a dual bronchodilator therapy used in the management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This combination contains Formoterol, a long-acting beta-2 adrenergic agonist (LABA), and Glycopyrrolate, a long-acting muscarinic antagonist (LAMA). Together, they work synergistically to relax the airway muscles, reduce mucus secretion, and improve airflow, making breathing easier and helping to prevent COPD exacerbations.
Mechanism of Action:
Formoterol works by stimulating beta-2 receptors in the airway smooth muscle, causing bronchodilation and sustained relaxation of the airways.
Glycopyrrolate blocks muscarinic receptors in the lungs, reducing bronchial secretions and preventing airway narrowing.
Therapeutic Uses:
Maintenance treatment of COPD
Relief from chronic symptoms such as breathlessness, wheezing, and coughing
Improvement of lung function and reduction in the frequency of exacerbations
Dosage Form:
Metered-Dose Inhaler (MDI) or Dry Powder Inhaler (DPI), depending on the formulation
Prescription Status:
Prescription-only medication
Note:
This medication is intended for long-term maintenance therapy and is not indicated for the relief of acute bronchospasm. It should be used regularly as prescribed by a healthcare professional, and proper inhalation technique is essential for optimal benefit.
Would you like this description adapted for use in marketing materials, digital listings, or regulatory documentation?
